Anand Parikh is a lawyer turned biotech entrepreneur and the CEO and co-founder of Faeth Therapeutics. He leads a new approach to cancer treatment that targets tumors’ metabolic vulnerabilities through precision diets paired with companion drugs. A graduate of NYU Law, Anand began his career in corporate law and public policy before joining Virta Health, where as CFO he helped scale a digital clinic using nutrition to reverse type 2 diabetes. Inspired by that success, he co-founded Faeth in 2019 with leading cancer metabolism researchers Lew Cantley, Karen Vousden, Sid Mukherjee, and Oliver Maddocks. Backed by over $60 million in funding, Faeth’s “MetabOS” platform integrates tumor genetics and dietary dependencies to improve efficacy and tolerability. Anand is passionate about patient-centered biotech and breaking paradigms in oncology, as Faeth’s clinical trials advance new options for endometrial, pancreatic, and colorectal cancer.
Two alternative approaches to drugging one of the most frequently dysregulated pathways in cancer have recently been gathering momentum in clinical development.